Cartesian Therapeutics (RNAC) Retained Earnings: 2015-2025
Historic Retained Earnings for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$729.8 million.
- Cartesian Therapeutics' Retained Earnings fell 7.04% to -$729.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$729.8 million, marking a year-over-year decrease of 7.04%. This contributed to the annual value of -$692.1 million for FY2024, which is 12.60% down from last year.
- Cartesian Therapeutics' Retained Earnings amounted to -$729.8 million in Q3 2025, which was down 5.17% from -$693.9 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Retained Earnings registered a high of -$392.9 million during Q2 2022, and its lowest value of -$729.8 million during Q3 2025.
- Over the past 3 years, Cartesian Therapeutics' median Retained Earnings value was -$671.5 million (recorded in 2024), while the average stood at -$612.1 million.
- As far as peak fluctuations go, Cartesian Therapeutics' Retained Earnings increased by 9.44% in 2022, and later slumped by 61.19% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Retained Earnings (Quarterly) stood at -$430.3 million in 2021, then increased by 8.22% to -$394.9 million in 2022, then plummeted by 55.63% to -$614.6 million in 2023, then fell by 12.60% to -$692.1 million in 2024, then fell by 7.04% to -$729.8 million in 2025.
- Its Retained Earnings was -$729.8 million in Q3 2025, compared to -$693.9 million in Q2 2025 and -$709.8 million in Q1 2025.